FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Meyers James R

2. Date of Event Requiring Statement (MM/DD/YYYY)
11/10/2016 

3. Issuer Name and Ticker or Trading Symbol

GILEAD SCIENCES INC [GILD]

(Last)        (First)        (Middle)

GILEAD SCIENCES, INC., 333 LAKESIDE DRIVE

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                            _____ 10% Owner
___ X ___ Officer (give title below)          _____ Other (specify below)
EVP Worldwide Commercial Ops /

(Street)

FOSTER CITY, CA 94404       

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed (MM/DD/YYYY)

 

6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person


Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4) 		2. Amount of Securities Beneficially Owned
(Instr. 4) 		3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5) 		4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock   6726   D    
Common Stock   121151   I   By Trust  

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4) 		2. Date Exercisable and Expiration Date
(MM/DD/YYYY) 		3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4) 		4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5) 		6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Non-qualified Stock Option (Right to Buy)     (3) 10/22/2017   Common Stock   60000   $21.00   D    
Non-qualified Stock Option (Right to Buy)     (3) 1/30/2018   Common Stock   100000   $21.575   D    
Non-qualified Stock Option (Right to Buy)     (3) 1/21/2019   Common Stock   60000   $23.60   D    
Non-qualified Stock Option (Right to Buy)     (3) 7/29/2019   Common Stock   60000   $24.905   D    
Non-qualified Stock Option (Right to Buy)     (3) 1/28/2020   Common Stock   53200   $23.755   D    
Non-qualified Stock Option (Right to Buy)     (4) 1/20/2021   Common Stock   67200   $19.085   D    
Non-qualified Stock Option (Right to Buy)     (4) 1/26/2022   Common Stock   48000   $24.295   D    
Non-qualified Stock Option (Right to Buy)     (4) 2/1/2023   Common Stock   34890   $40.56   D    
Non-qualified Stock Option (Right to Buy)     (4) 2/1/2024   Common Stock   25780   $80.65   D    
Non-qualified Stock Option (Right to Buy)     (4) 2/1/2025   Common Stock   17590   $104.83   D    
Non-qualified Stock Option (Right to Buy)     (4) 2/1/2026   Common Stock   17560   $84.05   D    
Non-qualified Stock Option (Right to Buy)     (4) 8/10/2026   Common Stock   15450   $78.90   D    
Restricted Stock Unit     (2)   (2) Common Stock   9780     (1) D    

Explanation of Responses:
( 1)  Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.
( 2)  The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested.
( 3)  The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested.
( 4)  The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Meyers James R
GILEAD SCIENCES, INC.
333 LAKESIDE DRIVE
FOSTER CITY, CA 94404

EVP Worldwide Commercial Ops

Signatures
/s/ Marissa Song by Power of Attorney for James R. Meyers 11/21/2016
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Gilead Sciences Charts.
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Gilead Sciences Charts.